Wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

IT2 - Exam 5 Dr.F Diabetic Treatment

Total questions: 28

Worksheet time: 18mins

Name
Class
Date
1.

To avoid therapeutic inertia reassess and modify treatment regularly

a)

2-6 months

b)

3-6 months

c)

6-8 months

d)

10-12 months

2.

If a patient has no comorbidities what would the 1st line be?

a)

Meformin

b)

Dulaglutide

c)

Empagliflozin

d)

Ertugliflozin

e)

Finerenone

3.

A patient with ASCVD/Indicator of high risk should be on?

a)

GLP-1

b)

SGLT2i

c)

Biguanide

d)

Insulin

4.

A patient with HF should be on?

a)

GLP-1

b)

SGLT2i

c)

Biguanide

d)

Insulin

5.

A patient with HF should avoid

a)

GLP-1

b)

SGLT2i

c)

Biguanide

d)

Saxagliptin

e)

TZD

6.

For CKD benefit a patient should be on:

a)

GLP-1

b)

SGLT2i

c)

Biguanide

d)

Saxagliptin

e)

TZD

7.

For CVD benefit a patient should be on:

a)

GLP-1

b)

SGLT2i

c)

Biguanide

d)

Saxagliptin

e)

TZD

8.

What agent can be used to reduce CKD progression and CV events?

a)

Meformin

b)

Dulaglutide

c)

Empagliflozin

d)

Ertugliflozin

e)

Finerenone

9.

To minimize hypoglycemia a patient should avoid:

a)

Insulin

b)

SU

c)

Empagliflozin

d)

Ertugliflozin

e)

Finerenone

10.

To minimize weight gain/promote weight loss a patient should be on:

a)

GLP-1

b)

SGLT2i

c)

Biguanide

d)

Saxagliptin

e)

TZD

11.

Which classes cause weight gain:

a)

GLP-1

b)

SGLT2i

c)

SU

d)

Insulin

e)

TZD

12.

Which of these is good to consider when cost and access is a factor

a)

GLP-1

b)

SGLT2i

c)

SU

d)

Insulin

e)

TZD

13.

If A1C is >10% OR BG >300 what should be used?

a)

GLP-1

b)

SGLT2i

c)

SU

d)

Insulin

e)

TZD

14.

Which of these is the MOST effective when considering weight loss?

a)

Semaglutide

b)

Liraglutide

c)

Dulaglutide

d)

Exenatide

e)

Lixisenatide

15.

Which of these is the LEAST effective when considering weight loss?

a)

Semaglutide

b)

Liraglutide

c)

Dulaglutide

d)

Exenatide

e)

Lixisenatide

16.

Which GLP1 should be used for ASCVD/Indicator of high risk?

a)

Dulaglutide

b)

Liraglutide

c)

Semaglutide

d)

Exenatide

e)

Lixisenatide

17.

Which GLP1 should be used for CVD benefit?

a)

Dulaglutide

b)

Liraglutide

c)

Semaglutide

d)

Exenatide

e)

Lixisenatide

18.

Which SGLT2i should be used for ASCVD/Indicator of high risk?

a)

Empagliflozin

b)

Canagliflozin

c)

Dapagliflozin

d)

Ertugliflozin

19.

Which SGLT2i is FDA approved for HF?

a)

Empagliflozin

b)

Canagliflozin

c)

Dapagliflozin

d)

Ertugliflozin

20.

Which SGLT2i is NOT FDA approved for HF but can still be used?

a)

Empagliflozin

b)

Canagliflozin

c)

Dapagliflozin

d)

Ertugliflozin

21.

Which SGLT2i is NOT FDA approved for CKD benefit but can still be used?

a)

Empagliflozin

b)

Canagliflozin

c)

Dapagliflozin

d)

Ertugliflozin

22.

Which SGLT2i is FDA approved for CKD benefit?

a)

Empagliflozin

b)

Canagliflozin

c)

Dapagliflozin

d)

Ertugliflozin

23.

Which SGLT2i is FDA approved for CKD benefit?

a)

Empagliflozin

b)

Canagliflozin

c)

Dapagliflozin

d)

Ertugliflozin

24.

Which SGLT2i can be used for CVD benefit?

a)

Empagliflozin

b)

Canagliflozin

c)

Dapagliflozin

d)

Ertugliflozin

25.

What is the peak for rapid acting insulin?

a)

1.5 h

b)

2 hr

c)

None

d)

6-7 hour

26.

What is the peak for short acting?

a)

1.5 h

b)

2 hr

c)

None

d)

6-7 hour

27.

What is the peak for long acting insulin?

a)

1.5 h

b)

2 hr

c)

None

d)

6-7 hour

28.

What is the peak for intermediate / NPH insulin?

a)

1.5 h

b)

2 hr

c)

None

d)

6-7 hour